drugset / Trial / NCT01270841

Normalization of Morning Testosterone Levels in Men With Secondary Hypogonadism

NCT01270841

Phase 2 Completed 83 enrolled Repros Therapeutics Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The Purpose of the study is to determine the effects of Androxal on morning testosterone and reproductive status in men with secondary hypogonadism(confirmed morning Testosterone less than 250 ng/dL), compared to changes with placebo, or Testim (topical testosterone). The effects of Testim versus placebo on reproductive status will also be examined. Study subjects must not be currently using a topical testosterone.

Timeline

Start
2011-01
Primary completion
2011-12
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Androxal Unknown 12.5 mg Oral
Subject Androxal Unknown 25 mg Oral
Comparator Testosterone Small molecule Topical